Download PDF
CC BY-NC-ND 4.0 · World J Nucl Med 2019; 18(02): 198-200
DOI: 10.4103/wjnm.wjnm_67_18
Case Report

Evaluation of recurrent parathyroid carcinoma: A new imaging tool in uncommon entity

N. T. K. Thanseer
0   Department of Nuclear Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India
,
Ashwin Singh Parihar
0   Department of Nuclear Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India
,
Ashwani Sood
0   Department of Nuclear Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India
,
Sanjay Kumar Bhadada
0   Department of Nuclear Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India
,
Divya Dahiya
0   Department of Nuclear Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India
,
Priyanka Singh
0   Department of Nuclear Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India
,
Bhagwant Rai Mittal
0   Department of Nuclear Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

Parathyroid carcinoma (PTC) is a rare endocrine tumor and uncommon cause for primary hyperparathyroidism.18F-fluorocholine (FCH) positron emission tomography and computed tomography (PET/CT) has shown promising results in the detection of parathyroid adenoma, though its role in PTC is undefined due to the paucity of incidence. The authors in this case report discuss the possible complimentary role of FCH PET/CT with 18F-fluorodeoxyglucose PET/CT in the evaluation of the management of suspected recurrence, since this rare entity has high loco-regional and distant recurrence of the disease.

Keywords

18F-fluorocholine - 18F-fluorodeoxyglucose - positron emission tomography and computed tomography - recurrent parathyroid carcinoma

Financial support and sponsorship

Nil.




Publication History

Received: 00 00 2019

Accepted: 00 00 2019

Article published online:
22 April 2022

© 2019. Sociedade Brasileira de Neurocirurgia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Wei CH, Harari A. Parathyroid carcinoma: Update and guidelines for management. Curr Treat Options Oncol 2012;13:11-23.
  • 2 Evangelista L, Sorgato N, Torresan F, Boschin IM, Pennelli G, Saladini G, et al. FDG-PET/CT and parathyroid carcinoma: Review of literature and illustrative case series. World J Clin Oncol 2011;2:348-54.
  • 3 Lezaic L, Rep S, Sever MJ, Kocjan T, Hocevar M, Fettich J, et al.¹8 F-fluorocholine PET/CT for localization of hyperfunctioning parathyroid tissue in primary hyperparathyroidism: A pilot study. Eur J Nucl Med Mol Imaging 2014;41:2083-9.
  • 4 Thanseer N, Bhadada SK, Sood A, Mittal BR, Behera A, Gorla AKR, et al. Comparative effectiveness of ultrasonography, 99mTc-sestamibi, and 18F-fluorocholine PET/CT in detecting parathyroid adenomas in patients with primary hyperparathyroidism. Clin Nucl Med 2017;42:e491-7.
  • 5 Deandreis D, Terroir M, Al Ghuzlan A, Berdelou A, Lacroix L, Bidault F, et al.¹8 Fluorocholine PET/CT in parathyroid carcinoma: A new tool for disease staging? Eur J Nucl Med Mol Imaging 2015;42:1941-2.
  • 6 Busaidy NL, Jimenez C, Habra MA, Schultz PN, El-Naggar AK, Clayman GL, et al. Parathyroid carcinoma: A 22-year experience. Head Neck 2004;26:716-26.
  • 7 Al-Sobhi S, Ashari LH, Ingemansson S. Detection of metastatic parathyroid carcinoma with tc-99m sestamibi imaging. Clin Nucl Med 1999;24:21-3.
  • 8 Arslan N, Rydzewski B. Detection of a recurrent parathyroid carcinoma with FDG positron emission tomography. Clin Nucl Med 2002;27:221-2.
  • 9 Gardner CJ, Wieshmann H, Gosney J, Carr HM, Macfarlane IA, Cuthbertson DJ, et al. Localization of metastatic parathyroid carcinoma by 18F FDG PET scanning. J Clin Endocrinol Metab 2010;95:4844-5.
  • 10 Calabria F, Chiaravalloti A, Schillaci O. (18)F-choline PET/CT pitfalls in image interpretation: An update on 300 examined patients with prostate cancer. Clin Nucl Med 2014;39:122-30.